Insider trade

Officer sold ~$273K of CYTK shares in the open market

Traded Mar 17, 2026 · Filed Mar 18, 2026

CytokineticsCYTK

~$273K
Approx. value · 4,397 sh @ $62.15: 154K
Holds after · shares reported: −1.3%
stock since the trade · S&P 500 +16.1%, $62.13 → $61.35 on Oct 6

Why it stands out

Cytokinetics's Research & Development sold $273K of Cytokinetics shares. The filing references tax withholding.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 17, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 18, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$273,274

Shares × reported transaction price

Timing vs results

21 days after results of Feb 24, 2026, 49 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references tax withholding

Only flagged when a footnote says so; never inferred

After it was reported

After	Stock	S&P 500	Difference
7 days	+0.8%	−2.2%	+3.1%
30 days	+5.1%	+7.4%	−2.3%
90 days	+24.1%	+12.3%	+11.8%
180 days	+10.1%	+14.8%	−4.7%

Past results only. Not a forecast.

Source receipt

Record ID: 0001061983-26-000027
Filed / recorded: Mar 18, 2026, 9:40 PM UTC
Added to OQRO: Oct 6, 2026, 7:14 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: CYTOKINETICS INC
Issuer CIK: 1061983
Ticker: CYTK
Reporting person: Fady Ibraham Malik
Relationship: Officer
Officer title: EVP Research & Development
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Mar 17, 2026
Transaction code: S
Shares / units: 4,397
Price per share: $62.15
Acquired / disposed: Disposed (D)
Shares owned after: 153,902
Ownership form: Direct
Amendment: No

Footnotes from the filing

Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

Around the same time

Nancy WysenskiDirector

Filed 6mo ago

95Shares · @ $65.37

Traded Apr 15 · filed the same day

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Wendell WierengaDirector

Filed 6mo ago

95Shares · @ $65.37

Traded Apr 15 · filed the same day

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Edward M. Md KayeDirector

Filed 6mo ago

191Shares · @ $65.37

Traded Apr 15 · filed the same day

Compensation award — excluded from discretionary-purchase analysis.

More Official record